Basic Search
|
Geographic Searches
|
Advanced Search |
Megadeals
Subsidy Tracker Parent Company Summary
Parent Company Name: Merck
Ownership Structure: publicly traded (ticker symbol MRK)
Headquartered in: New Jersey
Major Industry: pharmaceuticals
Specific Industry: pharmaceuticals
| Subsidy Summary | Subsidy Value | Number of Awards |
| State/Local | $143,089,367 | 78 |
| Federal (grants and allocated tax credits) | $0 | 0 |
| TOTAL | $143,089,367 | 78 |
| Loan / Bailout Summary | Total Face Value | Number of Awards |
| State/Local loans, bond financing and venture capital | $5,000,000 | 1 |
| Federal loans, loan guarantees and bailout assistance (not including repayments) | $0 | 0 |
| TOTAL | $5,000,000 | 1 |
Time Period for State and Local Awards: Earliest year of data: 1999. Availability of data for earlier years varies greatly from program to program. The majority of the listings for this parent company are for the period since 2012.
Time Period for Federal Awards: FY2000 to the present
Notes: Dollar totals do not include awards for which no subsidy value is disclosed.
Links: For a summary of this company's regulatory violations see its Violation Tracker summary page
here.
For an overview of this company's accountability track record, read its Corporate Rap Sheet
here.
For more details on misconduct by this company, see its entry in the Project On Government Oversight's
Federal Contractor Misconduct Database.
| Top 5 States for state/local awards | Total Subsidy $ | Number of Awards |
| North Carolina | $79,385,629 | 25 |
| Pennsylvania | $41,599,900 | 16 |
| New Jersey | $8,804,250 | 3 |
| Texas | $6,000,000 | 1 |
| Virginia | $5,089,383 | 6 |
| All other | $2,210,205 | 27 |
Individual Subsidy Records:
Click on the company name for more information on each subsidy award.
| Company | Location  . | Subsidy Source | Year | Subsidy Value | Loan/Bailout Value | Type of Subsidy |
| ILLUMIGEN BIOSCIENCES INC | Washington | state | 2004 | $11,367 | | tax credit/rebate |
| ILLUMIGEN BIOSCIENCES INC | Washington | state | 2005 | $4,341 | | tax credit/rebate |
| ILLUMIGEN BIOSCIENCES INC | Washington | state | 2006 | undisclosed | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2012 | $4,408 | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2013 | $4,304 | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2013 | $9,868 | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2014 | $22,572 | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2014 | $10,326 | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2015 | $10,326 | | tax credit/rebate |
| IMMUNE DESIGN CORP | Washington | state | 2016 | $10,326 | | tax credit/rebate |
| IMMUNE DESIGN CORP. | Washington | state | 2017 | $115,926 | | tax credit/rebate |
| IMMUNE DESIGN CORP. | Washington | state | 2018 | $115,926 | | tax credit/rebate |
| Merck | Virginia | state | 2007 | $1,500,000 | | grant |
| Merck & Co., Inc. | Virginia | state | 2010 | $89,383 | | training reimbursement |
| Merck Sharpe & Dohme | Virginia | state | 2016 | $1,300,000 | | grant |
| Merck & Co | Virginia | state | 2016 | $1,300,000 | | grant |
| Merck (2015) | Virginia | state | 2016 | $450,000 | | training reimbursement |
| Merck (2015) | Virginia | state | 2017 | $450,000 | | training reimbursement |
| Merck & Co., Inc. | Texas | state | 2017 | $6,000,000 | | grant |
| Merck & Co., Inc. | Pennsylvania | state | | $735,000 | | training reimbursement |
| Merck & Co., Inc. | Pennsylvania | state | | $265,000 | | training reimbursement |
| Cherokee Pharmaceuticals, LLC | Pennsylvania | state | | $699,000 | | tax credit/rebate |
| C3i Incorporated | Pennsylvania | state | | $458,000 | | tax credit/rebate |
| Cherokee Pharmaceuticals, LLC | Pennsylvania | state | | | $5,000,000 | loan or bond financing |
| Merck & Co., Inc. | Pennsylvania | state | | $1,200,000 | | grant |
| Cherokee Pharmaceuticals, LLC | Pennsylvania | state | | $1,200,000 | | grant |
| C3i Incorporated | Pennsylvania | state | | $400,000 | | grant |
| Merck & Co., Inc. | Pennsylvania | state | 2009 | $1,677,793 | | tax credit/rebate |
| Merck, Sharp & Dohme Corp. | Pennsylvania | state | 2010 | $1,321,420 | | tax credit/rebate |
| Merck, Sharp & Dohme Corp. | Pennsylvania | state | 2011 | $19,590,893 | | tax credit/rebate |
| Merck, Sharp & Dohme Corp. | Pennsylvania | state | 2012 | $10,263,039 | | tax credit/rebate |
| C3i, Inc. | Pennsylvania | state | | $500,000 | | grant |
| C3i, Inc. | Pennsylvania | state | | $512,000 | | tax credit/rebate |
| C3i, Inc. | Pennsylvania | state | 2014 | $512,000 | | tax credit/rebate |
| Merck, Sharp & Dohme Corp. | Pennsylvania | state | 2017 | $506,455 | | tax credit/rebate |
| MERCK SHARP & DOHME CORP | Pennsylvania | state | 2020 | $1,759,300 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2008 | $2,940,954 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2008 | $452,785 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2009 | $1,579,355 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2010 | $6,007,498 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2004 | $5,514,655 | | grant |
| Merck & Co., Inc. | North Carolina | state | 2008 | $770,277 | | tax credit/rebate |
| Inspire Pharmaceuticals, Inc. | North Carolina | state | 2008 | $14,500 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2004 | $24,000,000 | | grant/loan hybrid program |
| Merck & Co., Inc. | North Carolina | state | 2011 | $55,000 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2011 | $18,000 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2011 | $2,774,342 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2012 | $130,000 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2012 | $160,804 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2012 | $220,500 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 2012 | $6,651,352 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2013 | $1,230,023 | | tax credit/rebate |
| Merck & Co., Inc. | North Carolina | state | 1999 | $67,000 | | grant |
| Merck & Co., Inc. | North Carolina | state | 2001 | $33,000 | | grant |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2015 | $521,964 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2016 | $4,302,041 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2015 | $12,098,272 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2017 | $2,511,374 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. | North Carolina | state | 2018 | $2,189,941 | | tax credit/rebate |
| Merck Sharp & Dohme Corp. II | North Carolina | state | 2019 | $4,974,750 | | grant |
| Merck Manufacturing (project 6) | North Carolina | state | 2022 | $167,242 | | training reimbursement |
| C3I,Incorporated | New York | local | 2002 | $50,592 | | grant |
| OPTIMER PHARMACEUTICALS, INC. | New Jersey | state | | undisclosed | | tax credit/rebate; property tax abatement |
| Merck & Co., Inc. | New Jersey | state | 1999 | $874,000 | | grant |
| Merck & Co. Inc. | New Jersey | state | 2000 | $3,948,650 | | grant |
| Intervet Inc. | New Jersey | state | 2012 | $3,981,600 | | grant |
| C3I, Inc. | New Hampshire | state | 2012 | $9,105 | | training reimbursement |
| C3I | New Hampshire | state | 2014 | $9,576 | | training reimbursement |
| C3I | New Hampshire | state | 2015 | $5,908 | | training reimbursement |
| Intervet, Inc. | Nebraska | state | 2001 | undisclosed | | tax credit/rebate |
| Intervet, Inc. | Nebraska | state | 2007 | undisclosed | | tax credit/rebate |
| Intervet, Inc. | Nebraska | state | 2017 | undisclosed | | tax credit/rebate |
| Intervet, Inc. D/B/A Merck | Nebraska | state | 2019 | $500,000 | | grant |
| Merck Animal Health | Louisiana | state | 2012 | $995,624 | | property tax abatement |
| Intervet Inc. | Kansas | state | 2019 | undisclosed | | grant |
| Intervet Inc. | Kansas | state | 2020 | undisclosed | | tax credit/rebate |
| Intervet Inc. | Kansas | state | 2021 | undisclosed | | tax credit/rebate |
| Intervet Inc. | Kansas | state | 2022 | undisclosed | | tax credit/rebate |
| Intervet Inc. | Kansas | state | 2021 | $1,000 | | training reimbursement |
| Schering Corporation | Florida | state | 2007 | $84,000 | | tax credit/rebate |
| Intervet | Delaware | state | 2003 | $19,925 | | training reimbursement |
| Schering-Plough Animal Health Corporation | Delaware | state | 2006 | $21,485 | | training reimbursement |
| Schering-Plough Animal Health Corporation | Delaware | state | 2007 | $43,943 | | training reimbursement |
| Schering-Plough Animal Health Corporation | Delaware | state | 2008 | $45,400 | | training reimbursement |
| Intervet, Inc. | Delaware | state | 2011 | $29,450 | | training reimbursement |
| Intervet, Inc. | Delaware | state | 2013 | $16,236 | | training reimbursement |
| Intervet, Inc. | Delaware | state | 2015 | $29,352 | | training reimbursement |
| Intervet, Inc. | Delaware | state | 2016 | $28,919 | | training reimbursement |
| C3I, INC | California | local | 2012 | undisclosed | | tax credit/rebate |
